Raw materials: Patient-centric requirements for the supply of raw materials

Raw material variability and control of the supply chain are important issues for the biopharmaceutical industry. The industry is still at an early stage in the journey to align the supply base with biopharma's requirements to improve patient well-being by assuring product safety and meeting ever-increasing regulatory demands. This requires increased understanding, monitoring and control of raw materials. Patient well-being is best assured by reducing or eliminating variability of the finished drug product, and this can be achieved, in part by targeted reduction and/or elimination of variation in raw materials. Our challenge is to align the supply system to the patients' needs. This paper highlights 10 areas of practice endorsed by leading global biopharmaceutical manufacturers to start to address and reduce raw material variation through our supply chains. These are:

  • Patient-centered organizational culture
  • Control and elimination of sources of variation
  • Good Manufacturing Practice (cGMP)
  • Fit-for-purpose specifications
  • Change notification and early warning
  • Risk management
  • Traceability, transparency, and trust
  • Technical due diligence and audits
  • Root cause investigations
  • Data management

Patients have the right to expect safe and effective medicines as intended by the biopharmaceutical industry. This is the guiding principle of the Raw Material Variability workstream who recognize that the quality of raw materials can have a direct impact on the safety and efficacy of those medicines. An organizational culture that is patient-centric ensures that all parties along the supply chain make the patient's needs the center of all decisions.

The control and elimination of sources of variation in raw materials is essential to ensure patient safety and medicine efficacy as well as product quality and process performance. Collaboration across the supply chain is needed to achieve supply chain reliability and ensure that the correct processes and tools are in place to monitor and control variation. GMP code of practices assures that the proper design, monitoring, and control of processes and facilities are in place. Applying a good manufacturing practice mindset across the supply chain can help assure that raw materials are compliant with requirements for their intended use.

Suppliers and biopharmaceutical manufacturers need to work closely together to align a given raw material's specifications with the material's intended use. These specifications should be 'smart' in as much as they set appropriate tolerances for the material based on the process sensitivity to those raw material attributes. 'Fit for purpose' specifications is the aim but these need not be necessarily custom as maximizing the use of standard specifications can reduce cost, lead times and help address risks and quality concerns.

The supply chain of raw materials to manufacturers is inevitably affected by changes to the supply or the product; manufacturers need to be given sufficient warning and appropriate detail of the reasons for the change via an agreed and robust change notification and early warning process so that they can evaluate and plan for the impact of the change. Sometimes the suppliers do not know what impact a change will have on the manufacturing process which can result in either an increased burden on the manufacturer, or in the case of under notification, a detrimental effect on the manufacturing process and potentially the patient.

With the safety and efficacy of the drugs supplied to patients as a key tenet of the guidelines, risk management becomes essential requiring both suppliers and manufacturers to each asses their own supply chains to ensure understanding and ranking of the inherent risks.

An integrative and collaborative approach between suppliers and manufacturers is needed to make sure the understanding and mitigation of risks is aligned. The guidelines recommend a collaborative approach to mapping the supply chain to determine risks therefore increasing transparency, visibility and trust. This enables manufacturers to share the intended use of the raw materials with suppliers and harmonize material sources and specifications.

Establishing key supply partnerships is viewed as ideal as this can create value for both parties but it does require extensive sharing of information, integration of processes, and co-ordinated decision-making which is a significant move away from the traditional supplier-manufacturer relationship.

Currently manufacturers perform technical due diligence and audits on their suppliers as part of risk management. This includes a mutual review examining the essential material attributes of the raw material for its intended application; assessment of the supplier manufacturing processes; audits of supplier facilities and processes to ensure the robustness of the supply chains; audits of supplier controls including effective strategies for controlling the quality of the raw materials which includes the process and analysis, packaging, storage and shipping.

This audit process also looks at the processes surrounding change management and notification to manufacturers. In the event of a problem with the raw material, a root cause investigation must be carried out with an action plan to minimize the effect of the issue and prevent it from happening in the future. The type of root cause investigation conducted will depend on the severity of the issue especially if it entails a recall and both suppliers and manufacturers should apply the principles of 'Corrective and Preventative Action' (CAPA). The guide suggests that the success of this process depends heavily on the strength of the relationship between the manufacturer and the supplier and their shared accountability.

Manufacturing process and product related data plays a crucial role in enabling product improvements and process optimizations. Data management involving the sharing of scientific and technical expertise by suppliers with companies and regulators not only becomes part of the due diligence process but improves product understanding, identifies sources of variation and reduces raw material variability. Confidentiality agreements allow the exchange of data between suppliers and companies whilst adhering to data formats standards where they exist.

Attached Files

File
patient-centric-requirements-for-the-supply-of-raw-materials-into-biopharmaceutical-manufacturing.pdf
Preview
  • Version
  • Download 179
  • File Size 0.00 KB
  • File Count 1
  • Create Date 26th June 2015
  • DOI
  • Last Updated

Cell & Gene Therapy

Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.

We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C&GT-specific validation issues, as well as working toward resolving the current challenges to commercializing C&GT products. Discover more and learn about the outputs here.

Development Group

The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.

Drug Substance

Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives

Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.

Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.

Fill Finish

Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges.To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here. 

Information Technology

IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum. 

The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation. 

Regulatory-CMC

BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, filing and review, interactions with Health Authorities, and harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.

Supply Chain to Patient

The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.

Supply Partner

BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:

  • an enhanced robustness and resilience
  • accelerated capability and capacity to effect technology adoption
  • reduced cost of quality, and
  • industry-wide alignment on operational implementation

There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.

Sustainability

The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.

BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.

Technology Strategy

With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.

This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.

Best practices for demonstrating comparability for clinical cell-based therapies.

With the increased number of clinical trials using advanced novel cell-based therapies, much of the regulatory and industry guidance needs... read more

How to predict, optimize and analyze high-concentration biologic therapeutic formulations

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

A media fingerprinting toolbox that comes with a host of benefits

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

Why 100% visual inspection does not mean 100% defect detection

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

How to bridge the data integration gap between sponsors and contract organizations

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

Bringing BioPhorum’s unique perspective to continuous manufacturing in biologics

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

Supply Chain to Patient has launched!

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

Electronic data exchange – the foundation for an efficient, resilient inbound supply chain

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

How are you improving your environmental sustainability performance?

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

Adding value for analytical instrument partners

Raw materials: Patient-centric requirements for the supply of raw materials Raw material variability and control of the supply chain are... read more

Introducing MediPhorum

The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.

Advanced Wound Care and Wound Management

Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.

AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.

Drug Delivery

Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more
BioPhorum Deliverables Report
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
BioPhorum Downloads
Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.
Case Studies
Welcome to the BioPhorum case studies page, where you can learn how our clients have used our service to discover innovative solutions and save money. Here you can read real-life stories of how various organizations have used our unique data-driven approach to streamline their processes and make the most of their resources. Whether you're looking for inspiration or want to learn more about the potential benefits of our service, you'll find it here.
Webinars and podcasts
Welcome to BioPhorum Connect, the podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, this podcast brings you the insights and perspectives of experts from around the world. We'll discuss all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. So, join us on our journey as we explore the world of biopharmaceuticals and learn from the perspectives of those at the forefront of the industry.